- May 20, 2024 Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
- May 06, 2024 Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
- Apr 16, 2024 Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
- Apr 09, 2024 Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
- Apr 05, 2024 Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
- Mar 26, 2024 Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
- Mar 07, 2024 Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
- Mar 05, 2024 Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909
- Feb 28, 2024 Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
- Feb 08, 2024 Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
Displaying 11 - 20 of 22